PharmaPoint: Seasonal Influenza Vaccines United Kingdom Drug Forecast and Market Analysis

Description: PharmaPoint: Seasonal Influenza Vaccines United Kingdom Drug Forecast and Market Analysis

Summary

GlobalData has released its new Country report, “PharmaPoint: Seasonal Influenza Vaccines United Kingdom Drug Forecast and Market Analysis”. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

The British influenza vaccine market is valued at approximately $70.4 million in 2012. The expected drivers of growth include the recently announced influenza vaccine subsidies for children, launch of quadrivalent influenza vaccines and an increase in the elderly population.

The market leader is GSK's Fluarix. Fluarix has established itself atop the British influenza vaccine market due to GSK's home-field advantage, Fluarix's history of safe and effective use (available in UK since 1988), and Fluarix's low cost (almost 10% cheaper than the average cost of its competitors). GSK is expected to increase its UK market share with the introduction of a quadrivalent formulation of FluLaval in 2013.

Scope

- Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the UK from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the UK seasonal influenza market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012 to 2022 in the UK.

Contents:

1
1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis
4 Disease Management
4.1 Influenza Vaccination Policy
4.2 UK
4.2.1 Influenza Vaccination Recommendations and Policies
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands
5.3.1 Fluarix/FluLaval
5.3.2 Fluvirin
5.3.3 FluMist
5.3.4 Afluria
5.3.5 Vaxigrip/Mutagrip
5.3.6 Fluzone ID (Intradermal)
5.3.7 Agrippal
5.3.8 Optaflu
6 Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs
6.2.1 Higher level of patient awareness
6.2.2 Increased efficacy in the elderly and young children (<2 years old)
6.2.3 Improved vaccine side-effect profiles
6.2.4 More efficient vaccine manufacturing process
6.2.5 More cost-effective vaccines
6.3 Gap Analysis
6.4 Opportunities
6.4.1 Expanded breadth of protection against viral strains
6.4.2 Increased duration of protection
6.4.3 T-cell involvement
7 Pipeline Assessment
7.1 Overview
8 Market Outlook
8.1 United Kingdom
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Vaccine Coverage
9.4.2 Vaccines Included
9.4.3 Key Launch Dates
9.4.4 Influenza Vaccine Tender System Assumptions
9.4.5 General Pricing Assumptions
9.4.6 Individual Vaccine Assumptions
9.5 Physicians and Specialists Included in this Study
9.6 Primary Research - Prescriber Survey
9.7 About the Authors
9.7.1 Authors
9.7.2 Global Head of Healthcare
9.8 About Us
9.9 Contact Us
9.10 Disclaimer

1.1 List of Tables
Table 1: Notable Influenza Pandemics
Table 2: Symptoms of Influenza
Table 3: Influenza Vaccination Recommendation Committees by Country
Table 4: Leading Influenza Vaccines, 2012
Table 5: Product Profile - Fluarix
Table 6: Fluarix SWOT Analysis, 2012
Table 7: Product Profile - Fluvirin
Table 8: Immunogenicity of Agrippal and Fluvirin
Table 9: Fluvirin SWOT Analysis, 2012
Table 10: Product Profile - FluMist
Table 11: FluMist SWOT Analysis, 2012
Table 12: Product Profile - Afluria
Table 13: Afluria SWOT Analysis, 2012
Table 14: Product Profile - Vaxigrip
Table 15: Laboratory-Confirmed Influenza Infection Rates in Vaccine or Placebo Recipients and their Household Contacts
Table 16: Vaxigrip SWOT Analysis, 2012
Table 17: Product Profile - Fluzone ID
Table 18: Non-inferiority Comparison of Fluzone ID and IM Vaccines
Table 19: Fluzone ID SWOT Analysis, 2012
Table 20: Product Profile - Agrippal
Table 21: Agrippal SWOT Analysis, 2012
Table 22: Product Profile - Optaflu
Table 23: Optaflu SWOT Analysis, 2012
Table 24: Overall Unmet Needs - Current Level of Attainment
Table 25: Clinical Unmet Needs - Gap Analysis, 2012
Table 26: Sales Forecasts ($m) for Influenza Vaccines in the United Kingdom, 2012-2022
Table 27: Key Events Impacting Sales for Influenza Vaccines in UK, 2012
Table 28: Influenza Vaccine Market - Drivers and Barriers, 2012
Table 29: British Influenza Vaccine Uptake Scenarios for Childhood Influenza Vaccination Program, 2012-2022 (in millions)
Table 30: Key Launch Dates
Table 31: Physicians Surveyed, By Country

1.2 List of Figures
Figure 1: Influenza Virus Structure
Figure 2: Sales for Influenza Vaccines the United Kingdom by Route of Administration, 2012-2022

Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information

Please verify that the product information is correct and select the format(s) you require.

- **Product Name:** PharmaPoint: Seasonal Influenza Vaccines United Kingdom Drug Forecast and Market Analysis
- **Web Address:** http://www.researchandmarkets.com/reports/2368661/
- **Office Code:** SC6IYJR

Product Formats

Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>✔️</td>
<td>USD 4995</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>✔️</td>
<td>USD 9990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>✔️</td>
<td>USD 14985</td>
</tr>
</tbody>
</table>

Contact Information

Please enter all the information below in **BLOCK CAPITALS**

- **Title:**
  - [ ] Mr
  - [ ] Mrs
  - [ ] Dr
  - [ ] Miss
  - [ ] Ms
  - [ ] Prof

- **First Name:** __________________________
- **Last Name:** __________________________
- **Email Address:** * __________________________
- **Job Title:** __________________________
- **Organisation:** __________________________
- **Address:** __________________________
- **City:** __________________________
- **Postal / Zip Code:** __________________________
- **Country:** __________________________
- **Phone Number:** __________________________
- **Fax Number:** __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World